Ameriprise
AGN.PRA

Ameriprise’s Allergan plc AGN.PRA Stock Holding History

Ameriprise’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-38,968
Closed -$22.8M – 3774
2017
Q4 		$22.8M Sell
38,968
-5,912
-13% -$3.81M 0.01% 985
2017
Q3 		$33.1M Buy
44,880
+3,507
+8% +$2.91M 0.02% 733
2017
Q2 		$35.9M Buy
41,373
+1,337
+3% +$1.12M 0.02% 675
2017
Q1 		$34M Buy
40,036
+4,400
+12% +$3.65M 0.02% 695
2016
Q4 		$27.2M Sell
35,636
-9,386
-21% -$7.09M 0.01% 803
2016
Q3 		$37M Sell
45,022
-824
-2% -$712K 0.02% 630
2016
Q2 		$38.2M Sell
45,846
-96,627
-68% -$80.7M 0.02% 590
2016
Q1 		$131M Buy
142,473
+76,085
+115% +$72.7M 0.08% 254
2015
Q4 		$68.4M Buy
66,388
+1,760
+3% +$1.77M 0.04% 389
2015
Q3 		$61M Sell
64,628
-587
-0.9% -$612K 0.04% 409
2015
Q2 		$68M Buy
+65,215
New +$68.3M 0.04% 417

Other funds holding AGN.PRA

PWS
Peloton Wealth Strategists Indianapolis, Indiana $271M AUM 19.14% 1-Year Est. Return

Ameriprise's AGN.PRA Position: Q1 2018 in Review

Ameriprise sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 38,968 shares — an estimated $22.8M sold.

Ameriprise first reported a position in AGN.PRA in Q2 2015 and held it in 11 quarters. The position peaked at $131M in Q1 2016. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

  • Ameriprise reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
  • Ameriprise sold 38,968 Allergan plc shares in Q1 2018, an estimated $22.8M.
  • Ameriprise first reported a position in Allergan plc in Q2 2015 and held it in 11 quarters.
  • Ameriprise's Allergan plc position peaked at $131M in Q1 2016.
  • 1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on Ameriprise's 13F filing for Q1 2018, filed 15 May 2018.